Active Idiopathic Inflammatory Myopathy including dermatomyositis research hub

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy

This study is testing a new way to treat certain muscle diseases called inflammatory myopathies in adults and children. It looks at a special cell therapy (CABA-201) to see if it's safe and helps improve symptoms. Researchers want to understand how it affects the body.